Clinical effects of inhibiting leukocyte adhesion with monoclonal antibody to intercellular adhesion molecule-1 (enlimomab) in the treatment of partial-thickness burn injury

William Mileski, Deborah Burkhart, John L. Hunt, Richard J. Kagan, Jeffrey R. Saffle, David M. Heimbach, David Herndon, Arnold Luterman, Roger W. Yurt, Cleon W. Goodwin, John Hansborough

Research output: Contribution to journalArticle

42 Citations (Scopus)

Abstract

Background: A randomized, prospective, multicenter, double-blind, placebo-controlled, phase II clinical trial was performed to determine whether inhibition of leukocyte adherence by administration of monoclonal antibody directed against intercellular adhesion molecule-1 would improve burn wound healing. Methods: One hundred ten patients with burn injury ranging from 10% to 30% total body surface area were enrolled. Fifty-six patients received placebo (saline) and 54 patients received murine monoclonal antibody to the human intercellular adhesion molecule-1 (enlimomab). Treatment was initiated within 6 hours of injury. Patients had three distinct partial-thickness wound sites assessed. Laser Doppler flowmetry was used to stratify wounds on the day of injury. Wounds were assessed for healing status on day 21 postburn and categorized as healed, nonhealed, or grafted. Results: Patients treated with enlimomab had a significantly increased percentage of wounds that healed spontaneously in less than 21 days overall and when stratified by burn wound laser Doppler blood flow readings for those wounds at greatest risk for nonhealing. Conclusion: These results support the concept that leukocyte adherence is involved in the pathogenesis of burn wound necrosis and suggest a therapeutic mechanism for modulating the inflammatory response after the burn injury that may improve wound healing.

Original languageEnglish (US)
Pages (from-to)950-958
Number of pages9
JournalJournal of Trauma - Injury, Infection and Critical Care
Volume54
Issue number5
StatePublished - May 1 2003

Fingerprint

Intercellular Adhesion Molecule-1
Leukocytes
Monoclonal Antibodies
Wounds and Injuries
Therapeutics
Wound Healing
enlimomab
Placebos
Phase II Clinical Trials
Laser-Doppler Flowmetry
Body Surface Area
Reading
Lasers
Necrosis

Keywords

  • Burns
  • Intercellular adhesion molecule-1 (ICAM-1)
  • Laser Doppler
  • Leukocyte adherence

ASJC Scopus subject areas

  • Surgery

Cite this

Clinical effects of inhibiting leukocyte adhesion with monoclonal antibody to intercellular adhesion molecule-1 (enlimomab) in the treatment of partial-thickness burn injury. / Mileski, William; Burkhart, Deborah; Hunt, John L.; Kagan, Richard J.; Saffle, Jeffrey R.; Heimbach, David M.; Herndon, David; Luterman, Arnold; Yurt, Roger W.; Goodwin, Cleon W.; Hansborough, John.

In: Journal of Trauma - Injury, Infection and Critical Care, Vol. 54, No. 5, 01.05.2003, p. 950-958.

Research output: Contribution to journalArticle

Mileski, W, Burkhart, D, Hunt, JL, Kagan, RJ, Saffle, JR, Heimbach, DM, Herndon, D, Luterman, A, Yurt, RW, Goodwin, CW & Hansborough, J 2003, 'Clinical effects of inhibiting leukocyte adhesion with monoclonal antibody to intercellular adhesion molecule-1 (enlimomab) in the treatment of partial-thickness burn injury', Journal of Trauma - Injury, Infection and Critical Care, vol. 54, no. 5, pp. 950-958.
Mileski, William ; Burkhart, Deborah ; Hunt, John L. ; Kagan, Richard J. ; Saffle, Jeffrey R. ; Heimbach, David M. ; Herndon, David ; Luterman, Arnold ; Yurt, Roger W. ; Goodwin, Cleon W. ; Hansborough, John. / Clinical effects of inhibiting leukocyte adhesion with monoclonal antibody to intercellular adhesion molecule-1 (enlimomab) in the treatment of partial-thickness burn injury. In: Journal of Trauma - Injury, Infection and Critical Care. 2003 ; Vol. 54, No. 5. pp. 950-958.
@article{50696e61b11745bb9ddb829c127e13f0,
title = "Clinical effects of inhibiting leukocyte adhesion with monoclonal antibody to intercellular adhesion molecule-1 (enlimomab) in the treatment of partial-thickness burn injury",
abstract = "Background: A randomized, prospective, multicenter, double-blind, placebo-controlled, phase II clinical trial was performed to determine whether inhibition of leukocyte adherence by administration of monoclonal antibody directed against intercellular adhesion molecule-1 would improve burn wound healing. Methods: One hundred ten patients with burn injury ranging from 10{\%} to 30{\%} total body surface area were enrolled. Fifty-six patients received placebo (saline) and 54 patients received murine monoclonal antibody to the human intercellular adhesion molecule-1 (enlimomab). Treatment was initiated within 6 hours of injury. Patients had three distinct partial-thickness wound sites assessed. Laser Doppler flowmetry was used to stratify wounds on the day of injury. Wounds were assessed for healing status on day 21 postburn and categorized as healed, nonhealed, or grafted. Results: Patients treated with enlimomab had a significantly increased percentage of wounds that healed spontaneously in less than 21 days overall and when stratified by burn wound laser Doppler blood flow readings for those wounds at greatest risk for nonhealing. Conclusion: These results support the concept that leukocyte adherence is involved in the pathogenesis of burn wound necrosis and suggest a therapeutic mechanism for modulating the inflammatory response after the burn injury that may improve wound healing.",
keywords = "Burns, Intercellular adhesion molecule-1 (ICAM-1), Laser Doppler, Leukocyte adherence",
author = "William Mileski and Deborah Burkhart and Hunt, {John L.} and Kagan, {Richard J.} and Saffle, {Jeffrey R.} and Heimbach, {David M.} and David Herndon and Arnold Luterman and Yurt, {Roger W.} and Goodwin, {Cleon W.} and John Hansborough",
year = "2003",
month = "5",
day = "1",
language = "English (US)",
volume = "54",
pages = "950--958",
journal = "Journal of Trauma and Acute Care Surgery",
issn = "2163-0755",
publisher = "Lippincott Williams and Wilkins",
number = "5",

}

TY - JOUR

T1 - Clinical effects of inhibiting leukocyte adhesion with monoclonal antibody to intercellular adhesion molecule-1 (enlimomab) in the treatment of partial-thickness burn injury

AU - Mileski, William

AU - Burkhart, Deborah

AU - Hunt, John L.

AU - Kagan, Richard J.

AU - Saffle, Jeffrey R.

AU - Heimbach, David M.

AU - Herndon, David

AU - Luterman, Arnold

AU - Yurt, Roger W.

AU - Goodwin, Cleon W.

AU - Hansborough, John

PY - 2003/5/1

Y1 - 2003/5/1

N2 - Background: A randomized, prospective, multicenter, double-blind, placebo-controlled, phase II clinical trial was performed to determine whether inhibition of leukocyte adherence by administration of monoclonal antibody directed against intercellular adhesion molecule-1 would improve burn wound healing. Methods: One hundred ten patients with burn injury ranging from 10% to 30% total body surface area were enrolled. Fifty-six patients received placebo (saline) and 54 patients received murine monoclonal antibody to the human intercellular adhesion molecule-1 (enlimomab). Treatment was initiated within 6 hours of injury. Patients had three distinct partial-thickness wound sites assessed. Laser Doppler flowmetry was used to stratify wounds on the day of injury. Wounds were assessed for healing status on day 21 postburn and categorized as healed, nonhealed, or grafted. Results: Patients treated with enlimomab had a significantly increased percentage of wounds that healed spontaneously in less than 21 days overall and when stratified by burn wound laser Doppler blood flow readings for those wounds at greatest risk for nonhealing. Conclusion: These results support the concept that leukocyte adherence is involved in the pathogenesis of burn wound necrosis and suggest a therapeutic mechanism for modulating the inflammatory response after the burn injury that may improve wound healing.

AB - Background: A randomized, prospective, multicenter, double-blind, placebo-controlled, phase II clinical trial was performed to determine whether inhibition of leukocyte adherence by administration of monoclonal antibody directed against intercellular adhesion molecule-1 would improve burn wound healing. Methods: One hundred ten patients with burn injury ranging from 10% to 30% total body surface area were enrolled. Fifty-six patients received placebo (saline) and 54 patients received murine monoclonal antibody to the human intercellular adhesion molecule-1 (enlimomab). Treatment was initiated within 6 hours of injury. Patients had three distinct partial-thickness wound sites assessed. Laser Doppler flowmetry was used to stratify wounds on the day of injury. Wounds were assessed for healing status on day 21 postburn and categorized as healed, nonhealed, or grafted. Results: Patients treated with enlimomab had a significantly increased percentage of wounds that healed spontaneously in less than 21 days overall and when stratified by burn wound laser Doppler blood flow readings for those wounds at greatest risk for nonhealing. Conclusion: These results support the concept that leukocyte adherence is involved in the pathogenesis of burn wound necrosis and suggest a therapeutic mechanism for modulating the inflammatory response after the burn injury that may improve wound healing.

KW - Burns

KW - Intercellular adhesion molecule-1 (ICAM-1)

KW - Laser Doppler

KW - Leukocyte adherence

UR - http://www.scopus.com/inward/record.url?scp=0038198877&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0038198877&partnerID=8YFLogxK

M3 - Article

VL - 54

SP - 950

EP - 958

JO - Journal of Trauma and Acute Care Surgery

JF - Journal of Trauma and Acute Care Surgery

SN - 2163-0755

IS - 5

ER -